



# Objectives Describe major contraceptive issues for women Explain the pharmacological effects of different types of contraceptives Identify appropriate candidates for different methods of

Educate patients about contraceptive methods, use, and side effects

contraception









Becky is a 23-year old G0P0 female. She is in a new relationship and wants to start contraception. She has used condoms in the past, but wants to know about other methods.

Case 1: Becky



Effective
Able to continue method
Able to comply
Safe
Minimal counseling time




Easy to use
Safe
Effective
Minimal side effects
"Natural" method
Non-hormonal
Immediately reversible

\*Survey of 2,500 women from 5 countries

When considering pregnancy rates, differentiate typical use from ideal use



Perfect use is NOT real life!



### **Improving Success**

Choose methods requiring less attention

Counsel on expected side effects and management strategies

Remove barriers to initiation

\*No exam or Pap test

\*Quick Start initiation

\*No required f/u for refills

### When to Start a Contraceptive?

Method	When to start?	Back-up method
Combined pills	Any time if	If >7 days into
Progestin pills		
Nexplanon®	reasonably	cycle, use back-up method or abstain
DepoProvera®	certain women	for 7 days
Mirena®	is not pregnant*	
ParaGard®		Not needed

CDC, 2013.

### Is She Pregnant?

- ☐ Given birth in past 4 weeks?
- <6 mo postpartum AND fully breastfeeding AND free from menstrual bleeding since giving birth?</p>
- ☐ Last menstrual period started within past 7 days?
- ☐ Miscarriage or abortion in past 7 days?
- ☐ Abstinent since start of last menses?
- ☐ Using reliable contraceptive consistently/correctly?

Stanback et al. Lancet, 1999.




☐ Decreased libido

☐ Vaginal discharge, irritation


Case 1: Becky (cont'd)

Becky is in a stable, monogamous relationship. She works full-time and attends school at night.


She has no significant medical history and keeps a very regular schedule. She wants to talk about a hormonal agent.



# Combined Hormonal Contraception Side Effects (SE) Risks Breakthrough bleeding Blood clots (1-3/10,000) Nausea HBP (1/200) Headaches MI (women with CAD sx) Breast tenderness Stroke



### **Combined Hormonal Contraceptives Relative Contraindications** Uncontrolled "Classic" LDL cholesterol migraine HTN >160 Post-partum DM with <3 weeks or secondary Obesity early complications or breastfeeding duration >20 yr



### **Combined Oral Contraceptives (COCs)**



### Which COC to Choose?



Begin with a monophasic, 30-35 mcg.

### **FDA Drug Safety Warning** COCs with Drospirenone (DRSP)

May be associated with higher clot risk

• Additional risk beyond that associated with estrogen

Consider risks vs. benefits

- Can't tolerate other combined oral contraceptives
- Treat premenstrual dysphoric disorder (PMDD)

Not on VA formulary



### A note on COCs for women over 35...

- Safe for healthy nonsmokers
- Perimenopausal benefits
  - Regular menses
  - Improved BMD
  - Fewer vasomotor symptoms
  - Reduced cancer risk
- Discontinue age 50-55; 85% will be menopausal

### Patient Education all COCs



- Habit formation
- Side effects
- Backup x 7 days
- Meds that impact effectiveness
- No HIV/STI protection
- Missed pill protocol

### 7 9 10 11 12 8 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 8 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 • Side effects: spotting 29 30 31


### **Extended Cycle** Contraceptive

- Reduces menses frequency
- Thins endometrium
- Minimizes adverse experiences associated with menses
  - Heavy bleeding
  - Painful menses
  - Menstrual migraines

# Patient Education extended cycle COC



- Active pill x 84 days, inert pill x 7 days
- Spotting will decrease over time
- Can adjust week of menses



### **NuvaRing**<sup>®</sup>

- 2-inch vaginal ring
  - 15 mcg/day ethinyl estradiol
  - 120 mcg/day etonogestrel
- No fitting, special placement
- Wear 3 weeks out of 4
- Avoids OCP-associated nausea

## Patient Education NuvaRing®



- Schedule
- Insertion
- Side effects discharge
- Backup x 7 days
- Storage
- Product use issues
- No HIV/STI protection

### Ortho Evra Patch®



- Transdermal delivery
  - 20 mcg/day ethinyl estradiol
  - 150 mcg/day norelgestromin
- Worn 3 weeks out of 4
- · Changed weekly
- Efficacy affected by wt >90 kg
- Possible increased clot risk

Not on VA formulary

### Patient Education Ortho Evra Patch®




- Schedule
- Application sites
- Side effects, skin irritation
- Backup x 7 days
- Product use issues
- No HIV/STI protection

### **Unscheduled Bleeding**



- Often caused by contraceptive non-adherence
- Ranges from amenorrhea to heavy bleeding
- Identify underlying cause
- Treatment: NSAIDs, extra estrogen, alternative agents



### **Oral Progestin**



- Efficacy 91% lower?
- Inexpensive compared to injectable and implant
- Strict adherence to schedule
- Ok for breastfeeding moms
- Side effects mild

# Patient Education Oral Progestin



- Backup x 7 days at initiation
- Backup x 5 days if pill missed by >3 hrs
- No placebo week
- Irregular bleeding is common, may persist
- Potential amenorrhea
- No HIV/STI protection

Case 2: Melinda



Melinda is a 29-yo G2P2 female with a history of asthma. She keeps forgetting to take her pill. She doesn't want to have any more children, at least for the next few years.

What options does she have for hormonal long-acting reversible contraception (LARC)?

# Long-Acting Reversible Contraception (LARC)

Fewer unintended pregnancies

Safe

Economical

No ongoing effort by patient

Similar satisfaction

Better continuation rates

### Depo-Provera® (DMPA)



- 150 mg IM every 12-14 weeks
- Efficacy >94%
- R/O pregnancy before initiating and if >15 weeks elapse between injections
- Ok for immediate post-partum, after breastfeeding established
- No limit on duration; no need to monitor BMD
- · Weight-bearing exercise and calcium

### ADVANTAGES

### DISADVANTAGES

- High efficacy
- Dosing q 3 mo
- Decreased flow
- May reduce GYN cancers and PID
- Depo-Provera®

- Injection
- Weight gain, hair loss, mood changes, headache
- Initial irregular bleeding
- May increase uncontrolled depression
- Delayed fertility up to 1 yr
- Temporary reduced BMD
- ? thrombotic events


### Nexplanon® (etonogestrel)

- Implant in preloaded applicator
- Insert sub-dermally in arm
- Efficacy >99.5% for 3 years; no effect on BMD
- Ok for immediate postpartum contraception
- SE: irregular menses may not improve with time
- Insertion training through manufacturer

### Obtain from Prosthetics

- Trained provider
- R/O pregnancy
- Informed consent, written info
- Insertion/removal supplies
- Replace through same incision


### Nexplanon® Insertion/Removal



# Patient Education Nexplanon®



- Insertion 1 minute; removal 3 minutes
- Back-up x 7 days
- Side effects, irregular menses
- Remove no later than end of 3<sup>rd</sup> year. Record expiration date on user card; keep in safe place.
- Wound care
- No HIV/STI protection



### **IUD Contraindications**

 Distorted uterine cavity, active infection, copper allergy for ParaGard

• **NOT** contraindicated for nulliparas or women with history of STIs



### **IUD** Insertion

- Obtain from Prosthetics
- Trained provider
- R/O pregnancy
- 600-800mg ibuprofen 1hr before procedure
- Informed consent, written info
- Insertion/removal supplies
- STI screen if at risk

# Patient Education IUDs



- Irregular bleeding, cramping for 3-6 months
- Regular string checks
- Keep expiration date in safe place
- When to contact provider
- No HIV/STI protection
- Back-up x 7 days (Mirena)

### Mirena® IUD



- Levonorgestrel 20 mcg/day
- Efficacy 99.8% for 5 years
- SE: irregular bleeding and spotting; 20% amenorrhea by 1 year

### Skyla® IUD

- Levonorgestrel 14 mcg/day after 24 days
- Efficacy 99.1% for 3 years
- Slightly smaller than Mirena (28 x 30mm vs. 32 x 32 mm); insertion tube is also smaller (3.8 vs. 4.75mm)
- SE: irregular bleeding and spotting; 6% amenorrhea by 1 year

# Non-Contraceptive Uses of Mirena® and Skyla®

Decreases

Heavy menstrual bleeding

Menstrual pain


Bleeding and pain from fibroids

Risk of uterine cancer

# Case 2: Melinda (cont'd)



After reviewing her hormonal LARC options, Melinda wants to hear about non-hormonal options.



### ParaGard® – Copper T 380A IUD

- 380 copper coils
- Efficacy 99.2% for 10 years
- SE: minimal, rarely heavier menses, increased cramps
- Useful for women who decline hormones




### Male Condoms


- Popular with teens, 20-24 year olds, childless/never-married women
- · Cheap, easily to get
- STI protection (except lambskin)
- Failure rate 18%
- Disadvantages: break/slip, latex allergy
- Can order male condoms for women





Cervical cap photo courtesy of FemCap. Today sponge photo courtesy of Mayer Labs.













Lisa is a 26-yo G0P0 female with history of hypothyroidism. She calls your clinic first thing in the morning in a panic. She was having sex last night when the condom broke. She wants to know what to do.

How can you help her?

# Levonorgestrel: Plan B® and Next Choice® Copper IUD: ParaGard® Ulipristal: ella® Yuzpe method

### EC: Consider offering in advance

- Condoms break/slip/stay in the package
- Pills, patches, rings are forgotten
- Injection visits are missed
- Sex can happen when unexpected or uninvited
- Increases likelihood that EC is used
- Decreases time interval to use
- Does not increase risky behaviors or STI acquisition

# Guidance on Rights of Conscience (ROC) and Emergency Contraception VHA obligated to offer and provide EDA-approved to

- ☐ VHA obligated to offer and provide FDA-approved EC when medically indicated
- Individual clinicians may raise objections to providing EC based on ROC
- Clinician's claim to ROC cannot supersede patient's right to information about and access to EC when it is clinically indicated
  - VHA's official 2012 Information Letter providing guidance is expired with revisions pending

### Plan B One-Step<sup>®</sup>, Next Choice One Dose™

Levonorgestrel: 150 mcg or 1.5 mg

Take within 3 days; less effective but still useful day 4-5

Affects ovulation, fertilization, implantation

1.1% failure or 89% reduction

No risk to fetus if pregnant

Advanced provision: on VA formulary; refills ok

SE: heavier bleeding, nausea, abdominal pain, fatigue, headache

### ella® (Ulipristal)

- Selective progesterone receptor modulator
- Rx only
- Blocks ovulation, suppresses endometrial bleeding, induces endometrial changes that may detach products of conception
- May inhibit ovulation for up to 5 days
- Reduced efficacy as BMI increases to obese range (176 pounds)

### Other EC

### ParaGard®

- Place within 5 days (sooner the better)
- Failure rate 0.1 0.7%
- Retain for contraception
- Effective for obese women

### Yuzpe Regimen

• High dose of COC already on hand. More nausea/vomiting, less effective than Plan B®

# In summary, effective contraceptive counseling involves three steps...

- 1. Elicit patient's contraceptive goals
  - 2. Identify health risks for any options
    - 3. Determine patient's ability to consistently and correctly use preferred method



### **Authors**


Sherry Nordstrom, MD University of Illinois College of Medicine Chicago, IL

Kathleen McIntyre-Seltman, MD Pittsburgh VA Healthcare System Pittsburgh, PA

Contributors:

Linda Baier Manwell, MS University of Wisconsin School of Medicine & Public Health, Madison WI

Karen Goldstein, MD, MSPH Durham VA Medical Center, Durham NC





### **VA National Formulary Process**

- One VA National Formulary
  - \*NO VISN or local formularies\*
  - Goal: to provide a uniform drug benefit
- Non-formulary ≠ Not Available
- Formulary is meant to meet the needs of the majority of patients
- Some non-formulary use is expected
- · Use non-formulary request process if needed

VETERANS HEALTH ADMINISTRATION

EDUCATION & TRAINING

### **VA National Formulary Process**

- Formulary Addition:
- All New Molecular Entities reviewed
- Requests from VISN P&T or Chief Consultants
- Voting body:
  - Medical Advisory Panel
  - VISN Pharmacist Executives
- Ex: Contraceptives drug class review
  - Seasonale (and equiv) ADDED to VANF
  - Drosperinone-containing agents NOT added
    - Likely increased risk of TE events
    - Several alternatives on VANF
    - NF status prompts thoughtful consideration

EDUCATION & TRAINING

### **FAQs**

- How do I get a med added to CPRS ordering screen?
  - ADPAC, Pharmacy, Women's Health partnership
- Where can I find out about teratogenic meds?
  - CPRS Interim Order Check
  - CPRS TDrugs Permanent Solution (In production)
  - Reprotox: <a href="http://va.reprotox.us/">http://va.reprotox.us/</a>

VETERANS HEALTH ADMINISTRATION

EDUCATION & TRAINING

### **FAQs**

- Are condoms available?
  - Yes, both male and female condoms are available to all Veterans
- What contraceptives are on VA National Formulary?
  - Several pills, DMPA injection, vaginal ring
  - IUDs, implants available from Prosthetics
  - Levonorgestrel emergency contraception
  - https://vaww.cmopnational.va.gov/cmop/PBM/Clinical%20Guid ance/Clinical%20Recommendations/Contraceptive%20Agents,% 20Hormonal%20on%20VANF%20Jan%202013.doc

ETERANS HEALTH ADMINISTRATION

EDUCATION & TRAINING

### WH-Rx Collaboration

- Teratogenic meds alert
- Emergency contraception
- Women of childbearing age on warfarin
- Pharmacy Women's Health bootcamps
- Safety alerts (e.g., valproate)
- Local and VISN efforts
  - VISN 12 PharmD Lead for Women's Health
  - VISN 5 Direct Pharmacist Dispensing of EC

VETERANS HEALTH ADMINISTRATION

EDUCATION & TRAINING

### **Links and Contact Information**

• PBM Website:

https://vaww.cmopnational.va.gov/cmop/PBM/defaul t.aspx/


• Laura Esposito: laura.esposito@va.gov


• Chasitie Levesque: chasitie.levesque@va.gov


• Lisa Longo: lisa.longo@va.gov


VETERANS HEALTH ADMINISTRATION

EDUCATION & TRAINING













### AUB can be Acute or Chronic

### First determine acuity

- Acute bleeding is often associated with pregnancy complications and can be lifethreatening
  - · Evaluate as with any other acute bleeding
  - Requires immediate evaluation (but not always urgent)
- 2. Chronic bleeding allows time for work-up
  - · Evaluate systematically

# Acute Bleeding: Initial Steps 1. Evaluate for pregnancy • All women of reproductive potential\* require pregnancy testing 2. Assess for abnormal vital signs 3. Ask about abdominal/pelvic pain (i.e. ectopic) 4. Obtain objective evidence of blood loss \*VHA definition: 52 years and younger without documented hx of

hysterectomy or documented menopause (1 year menses free)

### **Objective Evidence of Blood Loss**

<u>For triage</u>, quantify bleeding by number of pads or compare it to normal menses

- Profuse bleeding: soaks large pad/tampon every 1-2 hours for ≥2 hours
- Prolonged uterine bleeding = bleeding for >7 days

For diagnosis, pad/tampon counts are unreliable

• CBC and ferritin are best ways of estimating blood loss

### **Urgent Cases**

ALL newly diagnosed pregnant women with abdominal pain and/or bleeding, should be evaluated immediately to rule out ectopic pregnancy

Re-check vitals frequently if heavy bleeding


If hemodynamically unstable with acute or prolonged bleeding...  $% \label{eq:control} % \label{eq:control}$ 

- Immediate intervention
- Transfer to acute care setting




# Chronic Bleeding

- Many women present with months of abnormal menstrual bleeding
- Goal of evaluation is to determine whether...
  - Normal menstruation, but unacceptable to patient
  - Ovulatory bleeding
  - Anovulatory bleeding



Cycle interval & bleeding duration should match Short interval between cycles = short bleeding duration **Follicular** • Estrogen-dominant phase • Endometrium proliferates Luteal · Progesterone-dominant phase Proliferation stops Long interval between cycles = long bleeding duration







### When to Work Up?

- Symptoms are problematic for the patient
  - Missing work
  - Avoiding social activities
  - Soiling clothes
- Iron deficiency anemia, suggesting significant chronic blood loss

## **Definitions** Menorrhagia (heavy menstrual bleeding) • blood loss > 80cc/cycle Intermenstrual bleeding bleeding/spotting between otherwise normal periods Menometrorrhagia • irregular and heavy bleeding







Jessica, who is 32-years-old, presents to your clinic with heavy vaginal bleeding x 4 days (soaking ~1 pad every few hours).

She appears hemodynamically stable during her initial nursing assessment with normal vitals.

She endorses 2/10 crampy pelvic pain typical of her usual menstrual cramps that began today. Her LMP was 4 weeks ago.

POC pregnancy test is negative.

### Characterize the Bleeding

**Ovulatory** (regular) *vs.* **non-ovulatory** (unpatterned) *Key to differential diagnosis, etiology, and management* 




### Menstrual charting helps assess:

- Frequency
- Duration
- Volume
- Nature of the bleeding

### Age of Patient

**Ovulatory** (regular): most common in reproductive years **Anovulatory** (unpatterned): frequent where failure to ovulate occurs (i.e., adolescent, premenopausal women)





### **Ovulatory Bleeding**

# Impaired endometrial hemostasis, focal or global Two patterns:

- 1. Menorrhagia
  - Excessive and/or prolonged blood loss at regular intervals
  - · May signify bleeding disorder or structural lesion

### 2. Intermenstrual bleeding

- Bleeding between regular cycles
- May be caused by cervical disease or IUD.
- Midcycle spotting may result from rapid decline in estrogen before ovulation

# Ovulatory Bleeding: Heavy Menstrual Bleeding

Normal menses is most common "etiology"

Hormonal imbalance → longer time between periods
 → increased estrogen exposure → heavy periods

Coagulopathies

Structural lesions (fibroids, adenomyosis, polyps, cancers)

Other (hypothyroidism, endometritis, endometriosis, hyperestrogenism)

Ovulatory Bleeding		
History	Physical	
Sexual activity Contraceptive use Pelvic pain Hypothyroid symptoms Bruising/bleeding Liver/renal disease Medications, herbals	Thyromegaly, dry skin & hair, diminished reflexes Bruising Abdominal/pelvic pain Vaginal/vulvar lesions, uterine enlargement, adnexal mass, cervical softening	

# All women with AUB require a pelvic exam



### Bleeding can emanate from:

- Vulva or vagina
- Uterus or cervix
- GI and/or GU tract
- · Localized trauma
- Tumor
- Manifestation of systemic disease
- Medication complication

### Ovulatory Bleeding: Lab Work

- · Pregnancy testing
- · CBC with platelets, ferritin
- PT/PTT, von Willebrand's screen
- TSH
- Pap, GC/Chlamydia tests
- Consider endometrial biopsy if >40 and/or risk factors for endometrial carcinoma





### **Risk Factors for Endometrial Cancer**

- Age >40 years
- FHx of uterine, breast, ovarian, colon cancer
- Obesity
- Bleeding >10 days or frequency <21 days
- Bleeding not regulated with hormonal therapy

### When to Biopsy?

Age 19-39	Endometrial cancer risk per 100,000 women = 2.3 - 6.1	Consider biopsy if chronic anovulation or unresponsive to medication
Age 40-49	Endometrial cancer risk per 100,000 women = 36	*unless pregnant/other reason to avoid sampling endometrium

ACOG. Int J Gynaecol Obstet, 2001.

### Ovulatory Bleeding: Management

Correct hypothyroidism

Refer lesions to gynecology

**NSAIDs** 

Combined hormonal contraceptives

Progesterone agents

\*Add an iron supplement if deficient.

# Ovulatory Bleeding Combined Hormonal Contraceptives



- Shortens long cycles to 28 days
   Less estrogen exposure → less endometrial proliferation
- All OCPs are combination pills

Therefore no unopposed estrogen exposure

### Ovulatory Bleeding: Progesterone

- Minimizes endometrial proliferation

  No unopposed estrogen
- Decreases overall bleeding


  Expect spotting until endometrium stabilizes
- Appropriate for women who can't or won't take estrogen-containing compounds

# Ovulatory Bleeding: Intermenstrual Bleeding

- OCP use (most common)
- Ovulation bleeding
- · Pelvic or vaginal infection
- Cervical or endometrial polyps
- Cancer

Postcoital bleeding suggests cervicitis, cervical polyps/cancer, ectropion


# Case 3 Irregular Uterine Bleeding 45-year-old





Becky is 45 years old.

She skipped the last two periods and has now been bleeding for the past 14 days.



### Anovulatory Bleeding: Menstrual Patterns

Ovulation is key for orderly menstruation

Ovulation → corpus luteum formation → progesterone

Anovulatory cycles can be interspersed with ovulatory cycles

• Absent premenstrual signs (e.g., bloating, breast pain)

~50% of perimenopausal women (>40) and 20% of adolescents experience anovulatory bleeding; both are due to estrogen withdrawal

### Anovulatory Bleeding: Menstrual Patterns

Can either present with no bleeding at all (amenorrhea) OR irregular/unpredictable bleeding of variable flow & duration

Sex hormones are produced but not cyclically

· Thus bleeding, but irregular bleeding



# Think of building a tower of blocks...

- Unopposed estrogen:
  - Endometrium proliferates unchecked
  - Endometrium is heavy and disordered → sloughing occurs
- Common at menarche and perimenopause

# Anovulatory Bleeding Differential Diagnosis

### Pregnancy, pregnancy, pregnancy!!!

Hypothalamic dysfunction

Ovarian dysfunction

Thyroid dysfunction

### **Anovulatory Bleeding**

History	Physical
Medication	• Obesity
<ul> <li>Sexual</li> <li>Contraceptive use</li> <li>Social</li> <li>Hirsutism, acne, hair loss</li> <li>Hot flashes, vaginal dryness</li> <li>Galactorrhea</li> </ul>	<ul> <li>Hirsutism, male pattern balding, acne</li> <li>Hyperthyroidism signs</li> <li>Breast discharge</li> <li>Vaginal atrophy</li> </ul>

### Reliability of Pregnancy Risk

- · History is notoriously unreliable
- ED study of women presenting with abdominal pain and menstrual bleeding...

swore no way they could be pregnant but 50% were!



# Pregnancy Determination



All women of reproductive potential with abnormal menses require pregnancy testing

Pregnancy testing is highly sensitive:

- Urine test 2 weeks after conception
- Serum test about 1 week after conception

### Anovulatory Bleeding: Lab Work

- Pregnancy testing
- TSH
- Prolactin
- · Free testosterone
- FSH and LH, if considering menopause



### Anovulatory Bleeding: Management

Treatment goals = regulate cycles, minimize blood loss, prevent iatrogenic complications from chronic unopposed estrogen

Treat underlying condition

- Thyroid dysfunction
- Bleeding disorder

Hor

- Hormonal management
- Combination contraception
- Progesterone: cyclic or IUD

# Anovulatory Bleeding Combined Hormonal Contraceptives



- · Restores orderly bleeding
- Prevents unopposed estrogen, thus checking uterine proliferation
- Provides contraception

### Anovulatory Bleeding: Management

### For women who can't or won't take OCPs...

- Cyclic progesterone
  - 10 days of medroxyprogesterone acetate every 30 days if no bleeding
- Progestin-containing IUD

# Case 4

Irregular Uterine Bleeding 25-year-old





Melinda, a 25-year-old woman, presents with irregular bleeding.

She has had only five menstrual cycles in the last 12 months and wonders if she's going through "early menopause".

She also complains about her weight, some hair loss, and acne.

### Polycystic Ovary Syndrome (PCOS)

Nearly 10% of women are affected

### Consequences for all phases of a woman's life

- Early irregular menses, obesity, hirsutism, acne
- Middle infertility, sleep apnea
- Late CVD, diabetes, endometrial cancer

### **PCOS Diagnostic Criteria**

### Rotterdam Criteria (any 2 of these 3):

- Anovulation or oligo-ovulation (<9 menses/year)
- Evidence of hyperandrogenism
- Polycystic ovaries (seen on pelvic ultrasound)
- · Does not include obesity/insulin resistance

# Some Perspective... Two thirds of cases have symptoms of anovulation Two thirds have hirsutism One half are obese Only one third have all 3 Rotterdam criteria Buggs & Rosenfield. Endocrinol Metab Clin North Am, 2005.

### **PCOS Differential Diagnosis**

**Hyperandrogenism, if pronounced** *signs and symptoms may signal...* 

Nonclassic congenital adrenal hyperplasia

**Cushing Syndrome** 


Adrenal or ovarian androgen-secreting tumors

# PCOS Diagnosis

Physical	Diagnostic Tests
• Obesity	• Pregnancy
<ul> <li>High blood pressure</li> </ul>	• TSH
Body hair, acne	• Total or free testosterone
<ul> <li>Enlarged ovaries</li> </ul>	• Prolactin
	• 17 OH progesterone
	• DHEAS
	• 2-hr GTT
	• Lipoproteins
	• Pelvic ultrasound


### **PCOS Management**

- Restore menses for endometrial protection
- · Manage hyperandrogenism
- · Treat infertility, if desired
- · Assess risk factors for CVD and DM



### Managing Hyperandrogenism

- · Weight reduction
- Antiandrogens
  - Spironolactone
- Combined hormonal contraception
  - Decrease ovarian androgen production, increase synthesis of SHBG



### The Metabolic Syndrome

### Any 3 of the following:

- Abdominal obesity (>35 inch waist)
- Blood pressure (>130/85mm Hg)
- Triglycerides (>150 mg/dl)
- HDL (<40 mg/dl)
- Fasting glucose (>100 mg/dl)

# The Metabolic Syndrome Prevalence in PCOS

47% of women with PCOS meet diagnostic criteria for the Metabolic Syndrome

Dokras et al. Obstet Gynecol, 2005.



# Why Does Metabolic Syndrome Matter?

- Pro-inflammatory
- Pro-thrombotic
- Increased risk for CVD and DM

### Diabetes in PCOS

- Study of obese women with PCOS:
  - 35% impaired glucose tolerance
  - 10% diagnosed with DM
- Subset of women repeated GTT after ~3 years:
  - 40% had deterioration in glucose tolerance

Ehrmann et al. Diabetes Care, 1999.

### Sleep Apnea

- Study of women with PCOS compared to premenopausal controls:
  - Sleep apnea significantly more common (OR 30.6!)
  - Difference remains even when controlling for BMI
  - Important to recognize the health consequences

Vgontzas et al. J Clin Endocrinol Metab, 2001.

### Managing CVD Risk in PCOS

Obese women need screening for Metabolic Syndrome and DM

- Waist measurement, BP, fasting lipids
- OGTT ideal; FBG and A1c alternatively

Ask about sleep apnea symptoms (even in women with normal BMIs)

Rotterdam Consensus Conference. Hum Reprod, 2004.

### Summary

AUB is common

Assess high acuity/risk

Determine ovulatory vs. anovulatory

Can be managed in primary care

Don't forget about contraception





Author: Melissa McNeil, MD, MPH

VA Pittsburgh Health Care System


Contributor: Linda Baier Manwell, MS


University of Wisconsin-Madison





















### **CPP** and Women Veterans

- 1 in 5 women veterans experience MST
- Women with MST are 2x as likely to have CPP


	No MST (n=2738)	MST (n=805)	Age-adjusted odds ratio
CPP	8%	17%	2.1 (1.7, 2.6)

Frayne et al. J Womens Health Gend Based Med 1999.







CF	PP is a Form of Chronic Pain
	Tissue injuries trigger chemicals leading to inflammatory reaction
	Pain signals carried by nociceptors synapse with spinal cord dorsal horn neurons
	Over time, changes in dorsal horn lead to allodynia and upregulation of pain fibers
	After pain becomes chronic, chronic pain model kicks in




GYN	GI	GU	Musculoskeletal
Endometriosis	IBS	Interstitial cystitis	Myofascial pain in abdomen or pelvic floor
Pelvic adhesions	IBD	Chronic UTI	Fibromyalgia
Chronic PID	Chronic constipation	Urethral syndrome	Coccygeal or low back pain
Adenomyosis	Colitis	Radiation cystitis	Nerve pain
Vulvodynia	Diverticulitis	Urinary calculi	
Ovarian cyst or varicosity	Differe	ntial Diagn	nosis of CPP
Uterine myoma		J	
Reiter R. Clin Obste	et Gyne 1990; Bo	ordman & Jackson	. Can Fam Phys 2006.









### Trauma-Informed Care: The Exam



- Monitor verbal/non-verbal cues of discomfort
- · Employ distractions
- Get permission before starting/resuming exam
- If signs of distress...

Would you like a minute to relax?
Would you like to delay rest of the exam?

### Physical Exam for CPP

General physical, looking for abnormalities


Pelvic exam, Pap (if due), specimens as indicated

**Bimanual** 

Try to reproduce the pain

Lack of PE findings doesn't rule out pathology


Zondervan et al. Obstet Gynecol 2004.





# Physical Exam Findings

- Palpation of outer pelvis can reveal trigger points suggesting myofascial component to pain
- Assess for nodularity, point tenderness or cervical motion tenderness on bimanual exam
- Rectal exam may show rectal or posterior uterine masses, nodularity, or pelvic floor point tenderness



# 20% of population 1.5x more common in women Onset <age 35 in 50% of cases</li> Poorer physical/mental health \$20 billion annually Irritable Bowel Syndrome (IBS) Abdominal discomfort + altered bowel habits for ≥3 months Descending colon Cecum Ascending colon Cecum Appendix Sigmoid colon Sigmoid colon



### **IBS Etiology**

- May be related to:
  - Motility
  - Absorption
  - Serotonin receptor activity
  - Bacterial infection
- Commonly occurs with endometriosis, interstitial cystitis, other female-predominant pain syndromes

History	Abdominal pain, bloating, cramping
	Diarrhea or constipation
Physical exam	Findings supporting other cause
Labs	Celiac disease
	Basic blood work
Colonoscopy	Consider, especially if warning
	symptoms

# IBS Diagnosis Rome Criteria

3 months abdominal pain/irritation that may be:

- Relieved with a BM
- Coupled with changes in frequency or stool consistency

Diagnosis: 2+ must be present ≥25% of the time:

- Change in frequency (>3 BM/day OR <3 BM/wk)
- Noticeable difference in stool form
- Mucous in stools
- Bloating or feeling of abdominal distention
- Altered stool passage (sensations of incomplete evacuation, straining, or urgency)

### Symptoms Suggesting Alternate Diagnosis



- Weight loss
- Anemia
- · Rectal bleeding
- Fever
- Nocturnal symptoms
- Onset >age 50
- Abrupt change in symptoms
- Family hx colorectal cancer

### **IBS Treatment**



- Dietary manipulation
  - Symptom diary to identify pain patterns
  - Elimination diet
  - Fiber (slowly work up to 30g per day over several weeks)
- Stress management

# IBS Treatment Medication Options

- Treat symptoms of diarrhea of constipation
- Tricyclic antidepressants
   +/- benefit in trials
- Antispasmodics
   Efficacy data lacking

Mayer EA. N Engl J Med 2008.



# IBS Treatment FDA-Approved Medications

- Alosetron (Lotronex®)
  - Diarrhea-predominant IBS
  - Risk of ischemic colitis limits use
- Lubiprostone (Amitiza®) and linaclotide (Linzess®)
  - Constipation-predominant IBS




Élie Metchnikoff first suggested colonizing the gut with beneficial flora in 1907

# IBS Treatment Probiotics

Meta-analysis of 10 RCTs (Moayyedi et al. *Gut*, 2010)

- Probiotics better than placebo (RR of IBS not improving 0.71, NNT=4)
- Magnitude of benefit, most effective strain, and ideal dose uncertain


Lactobacillus on VA formulary






- Dose 0.2-0.4 ml (200-400 mg) TID
- Enteric coated capsules
- Smooth muscle relaxant – can cause GERD


Merat et al. Dig Dis Sci 2010.










- Endometrial tissues (glands, stroma) appear outside uterus
- Usually confined to pelvis, but can occur elsewhere










# Endometriosis Diagnosis History Pelvic exam (tender pelvic structures, fixed retroverted uterus, adnexal masses, uterosacral ligament nodularity) Laparoscopy Other: CA-125, ultrasound, MRI




# Integrative Medicine Approach Stress management Support positive estrogen balance • Healthy weight Exercise >4 hrs/week











# Symptom and voiding diary Low potassium, low acid diet trial for 2 weeks Urinary alkalinization (Prelief® dietary suppl reduces acids) Increase water intake































Treatment for women with pelvic pain, regardless of etiology

### Lack of Evidence for CPP Management

No standard diagnostic algorithm for CPP

### Inadequate studies

- Not placebo-controlled
- Low participant numbers
- Etiology of CPP not defined prior to intervention
- Don't compare medical and surgical treatment

Andrews et al. AHRQ comparative effectiveness review no. 41, 2012.

### Non-Hormonal Pharmacologic Options

Diagnosed/undiagnosed/multifactorial CPP

• NSAIDs are first-line; try to avoid opioids

"Chronic pain medications"

- Gabapentin, amitriptyline most studied for CPP
- Topiramate, pregabalin, antidepressants can be considered

### **Hormone-Based Treatments**

For endometriosis, GnRH-agonists are better than OCPs alone

DMPA (Depo-Provera®): mixed evidence of benefit; ACOG supports use

If first-line therapy with OCPs or DMPA doesn't work, refer to GYN

ACOG practice bull #114, 2010; ACOG practice bull #110, 2010.

### **GnRH Agonists**

- Leuprolide (Lupron®)
  - SQ or IM (depot)
- Nafarelin (Synarel®)
  - Nasal spray
- Goserelin (Zoladex®)
  - SQ implant



"Add-back" HRT often used as GnRH agonists can cause a menopausal state and osteoporosis

### **Other Treatment Approaches**

Botulinum toxin A (not on VA formulary)

Pelvic floor physical therapy

### Integrative Medicine


 Organic, psychological, dietary, environmental causes and treatments for pain

### Treat PTSD

Shown to reduce other forms of chronic pain

### Surgery for Idiopathic CPP

- Presacral neurectomy
  - Up to 70% reduction in midline pain
  - Potential significant SE on bowel/ bladder function
- Hysterectomy
  - Supporting evidence is lacking





Andrews et al. AHRQ comparative effectiveness review no. 41, 2012.




### Multidisciplinary **Treatment Approach**

- Based on multiple causes of pain
- High prevalence of concomitant psychiatric dx
- Importance of clinician-patient relationship
- Inclusion of Mental Health, Integrative Medicine
- Counseling, support, ?group visits









### Authors:

Megan Gerber, MD, MPH VA Boston Healthcare System Jamaica Plain, MA

Sarina Schrager, MD, MS University of Wisconsin School of Medicine & Public Health, Madison, WI

### Contributors:

Linda Baier Manwell, MS University of Wisconsin School of Medicine & Public Health, Madison WI

Aimee Sanders, MD, MPH VA Ambulatory Care Center Columbus, OH

Megan Mcnamara, MD Louis Stokes VA Medical Center Cleveland, OH